- Atossa Therapeutics is clinical-stage biotech whose stock has trended a highly volatile path during the last one-year period.
- In addition to breast cancer research, where the company has been involved for years, it also focuses on producing nasal drops and inhalation therapy for combating COVID-19.
- Despite so many vaccines being available, alternatives still make sense in view of the coronavirus mutating rapidly and the limited immunity period conferred by current ones.
- There is sufficient cash to fund steadily rising R&D expenses.
- Currently below the $4 level, with its proprietary compounds constituting valuable assets, the company makes for investment in this COVID world.
For further details see:
Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World